Slaughter and May advised Shire - US$32 billion combination with Baxalta

Slaughter and May advised Shire plc in relation to its combination with Baxalta Incorporated. The combination has created a leading global biotechnology company focused on serving patients with rare diseases and other highly specialized conditions, projected to deliver double-digit top-line growth with over US$20 billion in annual revenues by 2020.

The transaction closed on 3 June 2016 after antitrust clearances were obtained from the European Commission and the competition authorities in the United States, Japan, Russia, Taiwan, Turkey and Jersey.

Baxalta shareholders received a combination of cash and Shire equity securities, representing an aggregate consideration of approximately $32 billion.

Ropes & Gray and Cravath, Swaine, & Moore also advised Shire. Kirkland & Ellis acted as transaction counsel and Jones Day acted as regulatory counsel to Baxalta.

Harry Hecht Partner
Matthew Tobin Partner
Azadeh Nassiri Partner
Charles Osborne Partner
Claire Jeffs Partner
Tina Zhuo Partner